Your browser is no longer supported. Please, upgrade your browser.
MyMD Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.83 Insider Own13.29% Shs Outstand35.91M Perf Week10.90%
Market Cap336.00M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float32.41M Perf Month14.53%
Income-27.20M PEG- EPS next Q- Inst Own17.30% Short Float2.50% Perf Quarter82.67%
Sales- P/S- EPS this Y68.80% Inst Trans19.46% Short Ratio3.04 Perf Half Y113.41%
Book/sh0.86 P/B10.17 EPS next Y- ROA-96.70% Target Price- Perf Year97.96%
Cash/sh0.56 P/C15.56 EPS next 5Y- ROE-105.70% 52W Range3.30 - 10.48 Perf YTD119.85%
Dividend- P/FCF- EPS past 5Y65.40% ROI- 52W High-16.51% Beta0.37
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low165.15% ATR0.59
Employees4 Current Ratio6.70 Sales Q/Q- Oper. Margin- RSI (14)64.44 Volatility7.27% 7.00%
OptionableYes Debt/Eq0.00 EPS Q/Q74.00% Profit Margin- Rel Volume0.57 Prev Close8.99
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume266.45K Price8.75
Recom- SMA2013.89% SMA5026.49% SMA20049.31% Volume150,839 Change-2.67%
Oct-19-21 10:30AM  
Oct-05-21 10:00AM  
Sep-22-21 11:00AM  
Sep-13-21 10:00AM  
Sep-09-21 10:15AM  
Aug-24-21 10:17AM  
Aug-23-21 08:47AM  
Aug-10-21 02:30PM  
Aug-05-21 10:30AM  
Jul-27-21 09:15AM  
Jul-07-21 09:00AM  
Jun-07-21 10:02AM  
May-17-21 09:00AM  
May-12-21 09:00AM  
May-10-21 09:00AM  
Apr-28-21 10:13AM  
Apr-22-21 09:20AM  
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, engages in the development of drug candidates to treat autoimmune, and aging and age-related diseases. It is developing MYMD-1, a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel diseases, as well as to treat age-related illnesses such as, frailty and sarcopenia. The company is also developing Supera-CBD, a synthetic preclinical cannabidiol derivative that targets CB2 receptors. The company is based in Baltimore, Maryland.